You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

SEVOFLURANE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Sevoflurane

A generic version of SEVOFLURANE was approved as sevoflurane by BAXTER HLTHCARE on July 2nd, 2002.

  Get Started Free

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for SEVOFLURANE?
  • What are the global sales for SEVOFLURANE?
  • What is Average Wholesale Price for SEVOFLURANE?
Drug patent expirations by year for SEVOFLURANE
Drug Prices for SEVOFLURANE

See drug prices for SEVOFLURANE

Recent Clinical Trials for SEVOFLURANE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Liaquat National Hospital & Medical CollegePHASE1
Xijing HospitalPHASE3
Ataturk UniversityNA

See all SEVOFLURANE clinical trials

Pharmacology for SEVOFLURANE
Drug ClassGeneral Anesthetic
Physiological EffectGeneral Anesthesia
Anatomical Therapeutic Chemical (ATC) Classes for SEVOFLURANE

US Patents and Regulatory Information for SEVOFLURANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare SEVOFLURANE sevoflurane LIQUID;INHALATION 075895-001 Jul 2, 2002 AN RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Shanghai Hengrui SEVOFLURANE sevoflurane LIQUID;INHALATION 203793-001 Nov 3, 2015 AN RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Halocarbon Prods SEVOFLURANE sevoflurane LIQUID;INHALATION 078650-001 Nov 19, 2007 AN RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Shandong SEVOFLURANE sevoflurane LIQUID;INHALATION 214382-001 Aug 18, 2023 AN RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for SEVOFLURANE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Chanelle Pharmaceuticals Manufacturing Limited Sevohale (previously known as Sevocalm) sevoflurane EMEA/V/C/004199For the induction and maintenance of anaesthesia. Authorised yes no no 2016-06-21
Zoetis Belgium SA SevoFlo sevoflurane EMEA/V/C/000072For the induction and maintenance of anaesthesia in dogs and cats. Authorised no no no 2002-12-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Market Dynamics and Financial Trajectory for Sevoflurane

Last updated: July 27, 2025

Introduction

Sevoflurane, a volatile liquid anesthetic agent, plays a crucial role in modern anesthesia practices worldwide. It is favored for its rapid onset, low blood solubility, and minimal renal and cardiovascular side effects. As a cornerstone in inhalational anesthesia, sevoflurane’s market dynamics are influenced by evolving clinical preferences, technological advancements, regulatory landscapes, and competitive pressures. This analysis explores the current market environment, growth drivers, challenges, and financial outlook of sevoflurane over the next decade to assist stakeholders in strategic decision-making.

Market Overview

Global Market Size and Growth Trends

The global inhalational anesthetics market was valued at approximately USD 1.1 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of around 4.2% from 2023 to 2030 [1]. Sevoflurane comprises a substantial portion of this market, owing to its widespread clinical adoption. Its dominance is supported by a preference for inhalational agents over intravenous anesthetics in certain surgical settings, driven by safety profiles and ease of titration.

Regional Market Distribution

North America dominates the sevoflurane market, accounting for over 40% of total revenue, underpinned by advanced healthcare infrastructure, high surgical volume, and robust adoption of modern anesthetic agents. Europe follows, buoyed by aging populations and increasing surgical procedures. The Asia-Pacific region exhibits significant growth potential, projected to grow at a CAGR exceeding 5%, owing to expanding healthcare access, increasing GDP, and rising awareness of anesthetic options [2].

Market Drivers

Advancements in Anesthesia Technology

Innovations in anesthetic delivery systems, such as precision vaporizers and closed-circuit anesthesia, bolster sevoflurane’s clinical utility. Its compatibility with modern anesthesia machines amplifies its attractiveness in both operating rooms and emerging healthcare markets.

Safety and Favorability Profile

Sevoflurane’s rapid induction and emergence facilitate efficient operating room turnover, increasing procedural throughput. Its minimal airway irritation and low solubility significantly reduce postoperative nausea and vomiting, factors contributing to its preference among anesthesiologists.

Growing Surgical Volume

The global increase in surgical procedures, particularly in orthopedic, cardiovascular, and neurological surgeries, sustains demand for inhalational anesthetics. Aging populations escalate the need for diverse surgical interventions, directly influencing sevoflurane consumption.

Regulatory Approvals & Patent Expirations

While originally patented in the 1990s, sevoflurane’s primary patents have expired, encouraging generic manufacturing. The cost competitiveness in generics enhances market accessibility, especially in price-sensitive regions.

Market Challenges

Environmental Concerns

Sevoflurane, like other volatile anesthetics, is a potent greenhouse gas. Its global warming potential (GWP) approximately 2,100 times that of CO₂ has prompted environmental scrutiny and calls for sustainable alternatives. This pressure may impact future regulatory policies and industry practices.

Competition from Alternative Agents

Total intravenous anesthesia (TIVA) agents such as propofol pose competition due to their ease of administration and reduced environmental impact. Moreover, newer inhalational agents like desflurane and isoflurane are also vying for market share based on specific clinical advantages.

Regulatory and Safety Regulations

Stringent regulatory oversight related to supply quality, environmental impact, and training standards can influence market dynamics. Variations across regions can create complexities in compliance and distribution.

Financial Trajectory & Market Opportunities

Forecasted Revenue Growth

Based on current trends, the sevoflurane segment is expected to grow at a CAGR of 4-5% through 2030 [3]. Revenue opportunities are especially prominent in the emerging markets of Asia-Pacific and Latin America, where infrastructural development and healthcare investments are accelerating.

Price Trends and Market Margins

The entry of generics has driven down prices, widening access but pressuring profit margins for branded producers. Manufacturers who leverage cost efficiencies, invest in sustainable practices, and expand into underserved regions can capitalize on profit growth.

Strategic Supply Chain and Manufacturing

Regional manufacturing hubs, particularly in India and China, have become integral to ensuring supply resilience and cost-effective production. Strategic partnerships and investments in environmental mitigation technologies will be critical to sustaining financial benefits.

Innovation and Diversification

Investment in research for low-GWP inhalational anesthetics or alternative delivery platforms presents future growth avenues. Companies that innovate beyond traditional formulations could capture niche markets and mitigate environmental regulations.

Regulatory Landscape and Future Outlook

Sustainability Initiatives

International agreements, such as the Montreal Protocol and Climate Change policies, influence anesthetic practice reforms. Industry players are exploring options like gas abatement systems or developing alternative agents with a lower GWP profile.

Market Entry and Competition Policies

Patent expirations catalyze competition but also prompt innovation. Regulatory agencies focus increasingly on environmental assessments, impacting the approval process and market entry strategies for new formulations.

Conclusion

Sevoflurane’s market remains robust, buoyed by clinical efficacy and safety profile. However, environmental considerations, competitive innovations, and regional healthcare development will shape its trajectory. Stakeholders poised to adapt through sustainable practices, technological innovation, and strategic regional expansion stand to capitalize on anticipated growth.


Key Takeaways

  • Market Growth: The global sevoflurane market is projected to grow at approximately 4-5% CAGR through 2030, driven by expanding surgical procedures and technological advancements.

  • Regional Opportunities: Asia-Pacific and emerging markets present significant upside due to rising healthcare investments and infrastructure development.

  • Competitive Edge: Companies should focus on cost efficiencies, sustainable manufacturing practices, and innovation in low-GWP anesthetics to sustain and grow market share.

  • Environmental Impact: Legislative and industry shifts towards sustainability will necessitate innovation in anesthetic delivery and broader environmental mitigation strategies.

  • Regulatory Adaptation: Navigating diverse regional regulations and promoting compliance will be crucial, especially concerning environmental standards and product approvals.


FAQs

  1. What factors influence the global demand for sevoflurane?
    Clinical safety profile, rapid onset and emergence, technological compatibility, expanding surgical procedures, and regional healthcare development primarily drive demand.

  2. How do environmental concerns impact the sevoflurane market?
    Its high GWP prompts regulatory scrutiny, leading to potential restrictions, increased adoption of environmentally friendly alternatives, and development of mitigation technologies.

  3. What role do generics play in sevoflurane’s market growth?
    Patent expirations have facilitated generic entry, reducing prices, enhancing access, and increasing overall market volume, although impacting branded profit margins.

  4. Are there ongoing innovations aimed at reducing sevoflurane’s environmental footprint?
    Yes, companies are researching low-GWP agents, gas reclamation systems, and alternative delivery methods to address environmental concerns.

  5. Which regions are expected to exhibit the highest growth for sevoflurane?
    The Asia-Pacific region is projected to lead due to increasing healthcare infrastructure, rising surgical volume, and favorable economic growth.


References

[1] MarketsandMarkets, "Inhalational Anesthetics Market," 2022.

[2] Research and Markets, “Global Anesthesia Market Analysis,” 2023.

[3] Grand View Research, "Anesthetics Market Size & Trends," 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.